BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 25665531)

  • 1. Involvement of mortalin/GRP75/mthsp70 in the mitochondrial impairments induced by A53T mutant α-synuclein.
    Liu FT; Chen Y; Yang YJ; Yang L; Yu M; Zhao J; Wu JJ; Huang F; Liu W; Ding ZT; Wang J
    Brain Res; 2015 Apr; 1604():52-61. PubMed ID: 25665531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of wild-type and A53T mutant isoform of alpha-synuclein on the mitochondrial proteome of differentiated SH-SY5Y cells.
    Pennington K; Peng J; Hung CC; Banks RE; Robinson PA
    J Proteome Res; 2010 May; 9(5):2390-401. PubMed ID: 20334438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotection of α-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K.
    Choong CJ; Say YH
    Neurotoxicology; 2011 Dec; 32(6):857-63. PubMed ID: 21658409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roflupram attenuates α-synuclein-induced cytotoxicity and promotes the mitochondrial translocation of Parkin in SH-SY5Y cells overexpressing A53T mutant α-synuclein.
    Zhong J; Li M; Xu J; Dong W; Qin Y; Qiu S; Li X; Wang H
    Toxicol Appl Pharmacol; 2022 Feb; 436():115859. PubMed ID: 34990728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells.
    Perfeito R; Lázaro DF; Outeiro TF; Rego AC
    Mol Cell Neurosci; 2014 Sep; 62():51-9. PubMed ID: 25109238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70.
    Albani D; Peverelli E; Rametta R; Batelli S; Veschini L; Negro A; Forloni G
    FASEB J; 2004 Nov; 18(14):1713-5. PubMed ID: 15345691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease.
    Xie W; Chung KK
    J Neurochem; 2012 Jul; 122(2):404-14. PubMed ID: 22537068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mitochondrial chaperone protein TRAP1 mitigates α-Synuclein toxicity.
    Butler EK; Voigt A; Lutz AK; Toegel JP; Gerhardt E; Karsten P; Falkenburger B; Reinartz A; Winklhofer KF; Schulz JB
    PLoS Genet; 2012 Feb; 8(2):e1002488. PubMed ID: 22319455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective effects of extract of Acanthopanax senticosus harms on SH-SY5Y cells overexpressing wild-type or A53T mutant α-synuclein.
    Li XZ; Zhang SN; Wang KX; Liu HY; Yang ZM; Liu SM; Lu F
    Phytomedicine; 2014 Apr; 21(5):704-11. PubMed ID: 24252343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.
    Martin LJ; Pan Y; Price AC; Sterling W; Copeland NG; Jenkins NA; Price DL; Lee MK
    J Neurosci; 2006 Jan; 26(1):41-50. PubMed ID: 16399671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism.
    Liu Z; Yu Y; Li X; Ross CA; Smith WW
    Pharmacol Res; 2011 May; 63(5):439-44. PubMed ID: 21237271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity.
    Smith WW; Jiang H; Pei Z; Tanaka Y; Morita H; Sawa A; Dawson VL; Dawson TM; Ross CA
    Hum Mol Genet; 2005 Dec; 14(24):3801-11. PubMed ID: 16239241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impairment of mitochondria dynamics by human A53T α-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease.
    Melo TQ; van Zomeren KC; Ferrari MF; Boddeke HW; Copray JC
    Exp Brain Res; 2017 Mar; 235(3):731-742. PubMed ID: 27866262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Mortalin Correlated with α-Synuclein as Serum Markers in Parkinson's Disease: A Pilot Study.
    Singh AP; Bajaj T; Gupta D; Singh SB; Chakrawarty A; Goyal V; Dey AB; Dey S
    Neuromolecular Med; 2018 Mar; 20(1):83-89. PubMed ID: 29307058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
    Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
    Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. splitGFP Technology Reveals Dose-Dependent ER-Mitochondria Interface Modulation by α-Synuclein A53T and A30P Mutants.
    Calì T; Ottolini D; Vicario M; Catoni C; Vallese F; Cieri D; Barazzuol L; Brini M
    Cells; 2019 Sep; 8(9):. PubMed ID: 31547305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. iTRAQ-based quantitative proteomics study on the neuroprotective effects of extract of Acanthopanax senticosus harm on SH-SY5Y cells overexpressing A53T mutant α-synuclein.
    Li XZ; Zhang SN; Wang KX; Liu SM; Lu F
    Neurochem Int; 2014 Jun; 72():37-47. PubMed ID: 24795107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A split-GFP tool reveals differences in the sub-mitochondrial distribution of wt and mutant alpha-synuclein.
    Vicario M; Cieri D; Vallese F; Catoni C; Barazzuol L; Berto P; Grinzato A; Barbieri L; Brini M; Calì T
    Cell Death Dis; 2019 Nov; 10(11):857. PubMed ID: 31719530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human A53T α-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neurons.
    Li L; Nadanaciva S; Berger Z; Shen W; Paumier K; Schwartz J; Mou K; Loos P; Milici AJ; Dunlop J; Hirst WD
    PLoS One; 2013; 8(12):e85815. PubMed ID: 24392030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitration of microtubules blocks axonal mitochondrial transport in a human pluripotent stem cell model of Parkinson's disease.
    Stykel MG; Humphries K; Kirby MP; Czaniecki C; Wang T; Ryan T; Bamm V; Ryan SD
    FASEB J; 2018 Oct; 32(10):5350-5364. PubMed ID: 29688812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.